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Introduction: Combined modality therapy is a standard therapy for
patients with unresectable stage III non-small cell lung cancer
(NSCLC). Gefitinib is active in advanced NSCLC, and in preclinical
models, it potentiates the activity of radiation therapy. We investi-
gate the tolerability of gefitinib in combined modality therapy in
combination with three-dimensional thoracic conformal radiation
therapy (3-dimensional TCRT).
Methods: Stage III patients with a good performance status were
treated with induction chemotherapy (carboplatin area under the
curve [AUC] of 5, irinotecan 100 mg/m2, and paclitaxel 175 mg/m2
days 1 and 22) with pegfilgrastim support followed by concurrent
chemotherapy (carboplatin AUC 2, and paclitaxel 45 mg/m2
weekly) and gefitinib 250 mg daily beginning on day 43 with
3-dimensional TCRT to 74 Gy.
Results: Between March 2004 and January 2006, 23 patients re-
ceived treatment on the trial: median age 62 years (range 44–82),
52% female, 61% stage IIIA, 61% performance status 0, 17% 5%
weight loss, and 91% underwent positron emission tomography
staging. Induction chemotherapy with pegfilgrastim support was
well tolerated and active (partial response rate, 24%; stable disease,
76%; and early progression, 0%). Twenty-one patients initiated the
concurrent chemoradiation, and 20 patients completed therapy to 74
Gy. The primary toxicities of concurrent chemoradiation were grade
3 esophagitis (19.5%) and cardiac arrhythmia (atrial fibrillation)
(9.5%). The median progression-free survival and overall survival
were 9 months (95% confidence intervals [CI]: 7–13 months) and 16
months (95% CI: 10–20 months), respectively.
Conclusions: Treatment with induction chemotherapy and gefitinib
concurrent with 3-dimensional TCRT has an acceptable toxicity and
tolerability, but the survival results were disappointing.
Key Words: High-dose radiation, Combined modality therapy,
Conformal radiation therapy, Epidermal growth factor receptor,
Tyrosine kinase inhibitor, Concurrent chemoradiotherapy.
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Lung cancer is the leading cause of cancer-related deaths inthe United States, and in 2007 it is estimated that more
people died from lung cancer than prostate, colorectal, and
breast cancer combined.1 Eighty-five percent of the cases of
lung cancer are non-small cell lung cancer histology
(NSCLC), and 30 to 45% will be stage IIIA or B at the time
of diagnosis, and are considered potentially curable.2,3 In the
United States, the standard of care for patients with a good
performance status is the combination of systemic dose che-
motherapy and thoracic radiation therapy, often referred to as
combined modality therapy.4 Unfortunately, the majority of
patients treated with combined modality therapy experience
locoregional or distant (or both) progression of their disease.
We have previously reported a phase I/II dose escalation
incorporating 3-dimensional thoracic conformal radiation
therapy (3-dimensional TCRT) into the treatment paradigm
of induction and concurrent carboplatin and paclitaxel.5 In
this trial, we successfully escalated the dose of 3-dimensional
TCRT from 60 to 74 Gy in 62 patients with unresectable
stage III NSCLC with an acceptable rate of acute and late
toxicities. The primary acute toxicity was esophagitis, but
only 8% of patients experienced grade 3 or 4 esophagitis. The
overall survival observed on this trial was encouraging, and
the median survival time was 25 months, and the 1-, 3-,
5-year survival rates with 95% confidence intervals (CI) were
71% (60–80%), 39% (27%–51%), and 26% (15%–38%),
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respectively.6 Despite the more aggressive locoregional treat-
ment, at least 35% of patients experienced locoregional
failures. A separate analysis of prognostic factors of patients
treated on our dose escalation trials revealed that the postin-
duction chemotherapy gross tumor volume (GTV) was pre-
dictive of survival.7 This observation provided the rationale
that a more aggressive induction chemotherapy treatment
may reduce the intrathoracic tumor volume before initiating
the chemoradiotherapy and improve locoregional control and
survival. Our subsequent stage III trial was a phase I trial
investigating further dose escalation of 3-dimensional
TCRT.8 On this trial, we incorporated induction chemother-
apy with carboplatin, paclitaxel, and irinotecan (CIP) with
growth colony stimulating factor for two cycles, which we
had previously investigated in advanced disease.9,10 The in-
duction therapy with growth colony stimulating factor sup-
port was well tolerated, and the rate of all toxicities was less
than 10%, and only 8% of cycles were complicated by grade
3 or 4 neutropenia.
At the time this trial was developed, gefitinib, an
epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI), had revealed promising activity in phase II
trials in patients with advanced NSCLC who had progressed
after one or two therapies.11,12 Two large phase III trials using
carboplatin/paclitaxel and cisplatin/gemcitabine with and
without gefitinib had been completed, but the survival results
were not available.9,10 Gefitinib appeared to be a promising
agent for the treatment of advanced stage disease, and pre-
clinical data indicated that the gefitinib may potentiate the
activity of radiation therapy.13–16 Given the safety and toler-
ability data from our previous trials, the combination of
induction chemotherapy with CIP, and concurrent chemo-
therapy with weekly carboplatin and paclitaxel with 3-dimen-
sional TCRT to 74 Gy appeared to be an appropriate treat-
ment paradigm to investigate gefitinib in the treatment of
unresectable stage III disease.
PATIENTS AND METHODS
Eligibility
Patients eligible for this trial were required to have a
cytologic or histologic diagnosis of stage IIIA or IIIB disease
and be deemed appropriate candidates for combined modality
therapy. All patients were reviewed by a thoracic radiologist,
pulmonologist, thoracic surgeon, radiation oncologist, and
medical oncologist. Initial staging consisted of a chest radio-
graph and a staging chest computed tomography (CT) scan,
which included full visualization of the liver and adrenal
glands. Radionuclide bone scans and/or positron emission
tomography (PET) scans were required as was either a CT or
magnetic resonance imaging scan of the brain. Patients with
supraclavicular adenopathy, superior sulcus tumors, or pleu-
ral effusion were excluded. Patients were required to have
Eastern Cooperative Oncology Group performance status of 0
or 1 and could not have received prior chemotherapy or
radiotherapy to the chest. Other required parameters were as
follows: absolute neutrophil count (ANC) 1500/mm3,
platelet count 100,000/mm3, serum creatinine 1.6 mg/dL
or Cockcroft calculated creatinine clearance 40 mL/min,
serum bilirubin 1.5 times upper limit of institutional nor-
mal, serum aspartate aminotransferase and alanine amino-
transferase 2.5 times upper limit of institutional normal.
Pulmonary function tests were required to document a forced
expiratory volume 1 second of 800 mL. Subjects taking
phenytoin, rifampin, barbiturates, carbamazepine, and St. John’s
Wort and patients with a prior malignancy who were disease free
5 years were excluded (except carcinoma in situ of the cervix
or breast and nonmelanomatous skin cancer). Of note, there was
not an inclusion or exclusion criteria related to weight loss.
Patients underwent a bronchoscopy, mediastinoscopy, or trans-
thoracic fine-needle aspiration for diagnosis and staging as
clinically indicated. This trial was approved by the Protocol
Review Committee of the Lineberger Comprehensive Cancer
Center (LCCC) and the Institutional Review Board of the
University of North Carolina School of Medicine and labeled
LCCC 0215. All patients provided informed consent before
enrollment on this trial.
Treatment Administration
Patients entered onto this trial received induction che-
motherapy with carboplatin area under the concentration
curve (AUC) of 5 by intravenous (IV) infusion using the
Calvert Equation,17 irinotecan 100 mg/m2 IV infusion, and
paclitaxel 175 mg/m2 IV infusion, all given on day 1 and 22.
Patients received pegfilgrastim 6 mg on the day 2 and 23 of
induction chemotherapy. Details of this regimen have been
published previously.18,19 On day 43, patients received 7 or 8
weekly treatments of paclitaxel 45 mg/m2/wk over 1 hour,
carboplatin AUC 2, and gefitinib 250 mg orally daily with
concurrent with TCRT. Treatment on days 22 and 43 required
an ANC of at least 1500/mm3 and platelets of at least 100,000/
mm3. A complete blood count was monitored weekly during
concurrent chemoradiotherapy. The carboplatin dose was re-
duced to an AUC of 1 if the ANC was 1000/mm3 but greater
than 500/mm3 or the platelets were 75,000/mm3. Both pacli-
taxel and carboplatin were held if the ANC was 500/mm3 or
the platelets were50,000/mm3. In the initial protocol, patients
continued to receive gefitinib 250 mg daily for 2 years or until
disease progression or unacceptable toxicity. The trial was
amended after an interim analysis of Southwest Oncology
Group (SWOG) trial 0023 by Data and Safety Committee of the
SWOG revealed that the addition of gefitinib after completion
of chemoradiotherapy in stage III disease did not improve
survival.20 The gefitinib was discontinued after completion of
TCRT, but was continued during the TCRT.
TCRT was initiated on day 43 concurrent with weekly
paclitaxel, carboplatin, and gefitinib as noted above. Patients
underwent a planning CT after the second cycle of chemo-
therapy. The initial clinical target volume (CTVI) was defined
as the prechemotherapy primary tumor volume, clinically
positive lymph nodes and the bilateral (elective) mediasti-
num. Clinically positive lymph nodes were defined as nodes
1 cm in greatest diameter visualized on CT scan, medias-
tinoscopy-positive or lymph nodes that were 1 cm and
positive on PET scan were included in the CTV1. The PET
scan was not used in the target volume delineation. The
elective mediastinum was defined as the mediastinum 0.5 to
2.0 cm below the clavicular heads to 1.0 to 2.0 cm below the
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carina or lowest clinically positive lymph nodes. The boost
clinical target volume (CTVB) was defined as the postinduc-
tion chemotherapy primary tumor and clinically positive
lymph node regions involved initially. The initial treatment to
the CTVI was performed using AP/PA (anteroposterior/pos-
teroanterior) fields. The CTVI received a dose of 44 Gy with
a 1.0 to 2.0 cm margin to account for subject motion,
registration inaccuracies, set-up variation, and dose build-up.
The total dose delivered to the CTVI was determined by a
spinal cord tolerance of 4750 cGy maximum. The boost
treatment was accomplished with oblique fields off cord with
a minimum of two beams. The off-cord boost received doses
of 74 Gy to the CTVB with a 1.0 to 2.0 cm margin. Patients
received 2 Gy/d Monday through Friday with the exception
of holidays with 6 MV photons. Dose limits for normal
tissue were as follows: no more than 35% of the lung volume
could receive 20 Gy (V20), no part of the spinal cord could
receive 50 Gy, and no part of the brachial plexus could
receive 66 Gy. The V20 was calculated using the total lung
volume defined as total lung minus the GTV. There were no
required dose limits on the treatment for the heart and the
esophagus; however, it was recommended that the entire
heart (and/or left ventricle) not receive 60 Gy, and the full
circumference of the esophagus not receive60 Gy for 6 cm.
Heterogeneity corrections were required in the treatment
planning. Patients did not receive intensity modulate radio-
therapy on this trial.
Response and Toxicity Evaluation
The response rate after two cycles of induction CIP was
assessed during week 6 of treatment with a staging chest CT
scan. All patients had a CT scan performed 2 months after the
last dose of TCRT were followed clinically every 2 months
with chest radiographs for the first 2 years. If patients had signs
on physical examination (eg, palpable lymphadenopathy) or
symptoms concerning for disease progression patients under-
went the additional testing including repeat CT scans of the
chest/abdomen, imaging of the brain, and bone scans as clini-
cally indicated. The date of progression was defined as the date
there was evidence of progression of disease on physical exam-
ination or radiographic imaging. Responses were assessed by
standard World Health Organization criteria.21 Toxicity was
assessed using the Common Toxicity Criteria scale version 2.0.
The primary dose-limiting toxicity was defined as grade 4
esophagitis.
Study Design and Statistical Design
The primary objective was to assess the toxicity and
tolerability of the combination of induction CIP with pegfil-
grastim supportive therapy, followed by concurrent carbopla-
tin, paclitaxel, and gefitinib with high dose 3-dimensional
TCRT in unresectable stage IIIA or B NSCLC. The second-
ary objectives were to estimate the overall and progression-
free survival. It was anticipated that esophagitis would be the
primary dose limiting toxicity (DLT), and the study was
designed to stop if the rate of grade 4 esophagitis was
statistically shown to be 10% at   0.091. Accrual and
continuous stopping rules were based on the primary DLT,
grade 4 esophagitis, and were as follows: 2 primary DLTs in
the first 3 subjects, 3 primary DLTs in the first 8 subjects, 4
primary DLTs in the first 14 patients, and 5 primary DLTs in
the entire cohort (n  20). Assuming a 20 to 30% noneva-
luable rate, 24 to 26 patients were required. In addition to the
stopping rules related to the primary DLT, there was an
additional stopping rule related to the failure to complete
protocol therapy: If 50% of patients who initiate treatment
had treatment delays of 2 weeks or did not complete
treatment due to toxicity, the trial would be stopped and
reviewed. Other grade 4 nonhematologic toxicities were eval-
uated during and for up to 90 days after initiation the
concurrent chemoradiotherapy, and were used to monitor for
excessive toxicity. The Kaplan-Meier (or product limit)
method was used to estimate the time to event functions of
progression-free survival and overall survival. Progression-
free survival has been defined as the time between the date of
the start of treatment to disease progression or death (which
ever occurs first) or the date of last contact. Overall survival
has been defined as the time from the date of the start of
treatment to the date of death or the date of last contact. Exact
95% confidence intervals were calculated for reported pro-
portions (or percentages) of interest. Statistical analyses were
performed with SAS statistical software, Versions 9.1, SAS
Institute Inc., Cary, NC. An analysis of molecular studies will
be provided in a separate article.
RESULTS
Patient Characteristics
Between March 2004 and January 2006, 24 patients
were enrolled on the trial, and one withdrew informed con-
sent before initiating therapy. Twenty-three received treat-
ment on the trial, and the demographic data are presented on
TABLE 1. Patient Demographics
Characteristic No. of Patients
Total no. of patients 23
Age (yr), median (range) 62 (44–82 yr)
Gender (male:female) 11:12
Race (white:African American) 19:4
Stage (IIIA:IIIB) 14:9





Large cell carcinoma 1 (4%)
Pulmonary function tests, median (range)
FEV1, l (range) 1.9 (0.86–3.79)
FVC, l (range) 2.78 (1.87–5.53)
DLCO (range) (mL/min/mm Hg)a 15.8 (2.17–32.7)
Smoking history (%)
Current smoker 8 (35%)
Former smoker 13 (56%)
Never smoker 2 (9%)
Positron emission scan staging 21 (91%)
a Data missing on one patient (n  22).
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Table 1. The median age was 62 years (range, 44–82).
Twelve of the patients (52%) were female, and 14 (61%)
were stage IIIA. Four patients (17%) had 5% weight loss,
and 21 patients (91%) underwent PET scan staging. The
majority of patients were former or current smokers (91%).
One patient experienced a grade 4 hypersensitivity reaction
related to paclitaxel and did not continue treatment on the
trial, and one patient received one cycle of induction therapy
on the trial and was subsequently found to be ineligible; 21
patients started and were considered evaluable for assessing
the tolerability and toxicity of concurrent chemoradiotherapy
in combination with gefitinib.
Induction Chemotherapy
Twenty-three patients received at least one treatment of
CIP induction chemotherapy, and 43 cycles were given. The
hematologic and nonhematologic toxicities are shown in
Table 2. In general, the hematologic toxicities with induction
CIP with pegfilgrastim supportive therapy were mild and
acceptable. Only 2% of cycles were complicated by grade 3
or 4 neutropenia. The primary grade 3 or 4 nonhematologic
toxicities were nausea, vomiting, and diarrhea, each of which
complicated 7% of all cycles. Twenty-one patients were
evaluable for response to induction CIP. Five patients had a
partial response (response rate of 24%, 95% confidence
interval [CI]: 8–47%), and the remaining 16 patients had
stable disease (stable disease rate of 76%, 95% CI: 53–92%).
Of note, no patients experienced disease progression during
the first two cycles. The median prechemotherapy GTV was
98 mL (range, 6–305 mL), and the median postchemotherapy
GTV was 64 mL (range, 6–215 mL). This represents a
reduction in the median GTV of 35%.
Concurrent Chemoradiation Toxicity
Twenty-one patients initiated the concurrent chemora-
diation, and 20 patients completed therapy. One patient de-
veloped a pulmonary embolism and became supratherapeutic
on anticoagulation and developed a hemorrhagic pericardial
effusion and did not complete the concurrent chemoradio-
therapy to 74 Gy. The primary toxicities were grade 3
esophagitis (19.5%), and cardiac arrhythmia due to atrial
fibrillation (9.5%) (Table 3). Twelve patients initiated the
maintenance gefitinib before the amendment, and patients
received a median of 2 months of maintenance gefitinib
(range, 1–4 months). Three patients developed late compli-
cations, defined as developing or persisting 60 days after
completion of radiation therapy (grade 3 esophageal [n  2];
grade 3 anterior spinal cord syndrome due to probable spinal
cord infarct [n  1]) within the radiation field. The patient
presented with anterior spinal cord syndrome 8 months after
completion 3-dimensional TCRT and 2 weeks after discon-
tinuing gefitinib. She presented with symptoms of lower
extremities weakness and tingling for 1 to 2 months and new
onset urinary retention. The patient received radiation therapy
dose at the maximum point of 4708 cGy from the APPA
fields, and the total delivered including the scatter dose from
the oblique fields was 4957 cGy. The patient was evaluated
with magnetic resonance imaging of the spine, which was
negative for cord compression, a lumbar puncture, which was
negative for malignant cells, B12 and folate were within
normal limits, and rapid plasma regain and hypercoaguable
work-up was negative.
Progression-Free and Overall Survival
Of a total of 23 patients who had been followed for
survival information, 19 have died and 4 were still alive at the
time of analysis (Figure 1). Three survivors were alive more
than 30 months out from the date of the start of treatment.
The median follow-up time for survivors was 30 months. Of
the 19 patients who have died, 15 have been documented to
have progressed earlier, and 4 have died without evidence of
progression. A total of 20 have either progressed or died
















Pericardial effusiond 4.8 0
Elevated prothrombin timed 4.8 0
Embolismd 0 4.8
Hematemesis 4.8 0
All values reported are in percentages.
a Atrial fibrillation in both cases.
b Determined to be radiation induced pneumonitis.
c Infection without neutropenia (herpes simplex virus meningoencephalitis).
d All these events occurred in a single patient.













Hypersensitivity reactions 0 2
a Numbers represent percentage of cycles in which the toxicity occurred.
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(Figure 2). Median progression-free survival time was 9
months (95% CI: 7–13 months), and median overall survival
time was 16 months (95% CI: 10–20 months). Three patients
experienced local progression, one patient experienced local
and distant progression, and 11 patients experienced distant
progression.
DISCUSSION
This trial did meet the primary end-point of demon-
strating that gefitinib can safely be integrated into combined
modality therapy without excessive toxicity or a significant
number of patients failing to complete the prescribed treat-
ment. However, the median survival time was disappointing
in comparison to our previous trial and the recent trials that
have used a similar treatment paradigm (Table 4).5,22–25 A
recent retrospective analysis of patients (n  112) treated on
4 of our phase I/II or II combined revealed a median survival
of 24 months (95% CI: 18–31 months) and 5-year survival
rate of 24% (95% CI: 16–33%).26 The increased use of PET
scans (91% of patients) alone on this trial should have in
improved survival due to superior staging techniques in
comparison to our previous trials. The eligibility criteria are
similar to our previous trials, which should have reduced the
chance of any significant differences in the patient population
on this trial from our previous trials. However, other unrec-
ognized prognostic factors or changes in physician patient
selection may have influenced enrollment and contributed the
lower than expected survival, especially given the relatively
small size of the trial. Of note, 4 of the 23 enrolled on this
trial had 5% weight loss, which has been identified as a
poor prognostic factor in combined modality trials.24 Impor-
tantly, this trial differs from standard therapy is several
aspects: the use of a more aggressive three drug induction
therapy, the use of pegfilgastrim supportive therapy, in-
creased dose of TCRT (74 Gy while the standard dose was 60
Gy), and the use of gefitinib concurrent with TCRT. It is
difficult to determine whether one or a combination of these
factors may have adversely impacted the survival.
One concern is that the treatment with gefitinib ad-
versely impacted the survival of patients on this trial. At the
same time, this trial was being performed SWOG, Cancer and
Leukemia Group B (CALGB), and Australian centers were
performing trials with gefitinib in combination combined
modality therapy (Table 5).27–29 Patients on the SWOG trial
FIGURE 1. Overall survival with 95% confidence intervals.
FIGURE 2. Progression-free survival with 95% confidence
intervals.
TABLE 4. Recent Trials of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy
Trial N Induction Chemotherapy Concurrent Chemotherapy TRT Dose (Gy) Median Survival (mo)
LCCC 96035 62 Carboplatin/paclitaxel Carboplatin/paclitaxel weekly 60–74 24
LCCC 20018 29 Carboplatin/paclitaxel  irinotecan Carboplatin/paclitaxel weekly 78–90 24
CALGB 3980124 366 Arm A – none Carboplatin/paclitaxel weekly 66 12
Arm B – carboplatin/paclitaxel Carboplatin/paclitaxel weekly 14
CALGB 3010537 69a Arm A – carboplatin/paclitaxel Carboplatin/paclitaxel weekly 74 24
Arm B – carboplatin/gemcitabine Gemcitabine twice/wk 14
BCTG25 276 Carboplatin/paclitaxel RT alone 60 14.1
Paclitaxel weekly 18.7
RTOG 98-0123 243 Carboplatin/paclitaxel Carboplatin/paclitaxel weekly 69.6b 17.5
a Forty-three patients on Arm A, 26 patients on Arm B. Arm B closed early due to excessive toxicity.
b TRT  69.6 Gy at 1.2 Gy BID.
CALGB, Cancer and Leukemia Group B; LCCC, Lineberger Comprehensive Cancer Center; BCTG, Bronchial Carcinoma Therapy Group; RTOG, Radiation Therapy Oncology
Group; TRT, Thoracic Radiation Therapy.
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were treated with concurrent chemoradiotherapy and consol-
idation docetaxel, and were then randomized to maintenance
gefitinib (n  118) or placebo (n  125). With a median
follow-up of 27 months patients randomized to the gefitinib
arm had a worse overall survival than the placebo arm:
overall survival from time of randomization 23 versus 35
months, respectively (p  0.01). The primary cause of the
poor survival on the gefitinib arm was an excessive number of
deaths due to progressive disease. There did not appear to be
any difference in the baseline characteristics between the two
treatment arms at time of randomization. On our trial, only 12
patients of the 23 patients received maintenance gefitinib for
a median of 2 months (range, 1–4 months); thus, it is difficult
to determine whether maintenance gefitinib contributed to the
disappointing survival on our trial.
The CALGB trial was a phase II trial with two cohorts,
and patients were stratified based on clinical characteristics
(stratum 1 and 2).27 This trial was closed after the interim
results of SWOG 0023 were announced. The patients on
stratum 2 (n  39) were a similar patient population and
received a similar treatment to the patients on our trial; the
median progression-free survival was 9.2 months, 1-year
survival rate was 47%, and median overall survival was 12
months. An Australian multicenter phase I trial investigated
the combination of thoracic radiation therapy (60 Gy) and
gefitinib 250 mg daily with carboplatin (AUC  2) weekly in
the first cohort, and gefitinib 250 mg daily, carboplatin (AUC 2)
weekly and escalating doses of paclitaxel (25, 25, 45 mg/m2)
weekly on cohorts 2, 3, and 4, respectively.29 All patients
were required to have stage III disease, good functional
status, and weight loss 10%. No dose-limiting toxicities
were observed, and all patients received 60 Gy. A total of 28
patients were enrolled, and the fourth cohort (gefitinib 250
mg daily, carboplatin (AUC  2) weekly, and paclitaxel 45
mg/m2 weekly) was expanded (n  16). The median survival
for all patients on the trial has not been reached, and the
2-year survival rate is 60% (95% CI: 39–82%).
The increased number of cancer deaths seen on the
SWOG trial and the relatively low median survival times on
our and the CALGB trials is concerning. The combination of
treatment with radiation therapy and concurrent gefitinib or
subsequent gefitinib may fundamentally alter the biology of
the NSCLC. Several groups have demonstrated the develop-
ment of “acquired resistance” due to the development of a
secondary mutation resulting in threonine to methionine at
790 (T790M) of EGFR.30–32 This mutation has been reported
to be present at the time of diagnosis in some patients as
well.33 Preclinical and anecdotal clinical evidence indicates
that tumors with this mutation may have a more aggressive
behavior.34,35 Focal amplification of the MET proto-oncogene
has also been detected in lung cancer specimens from patients
who were initially demonstrated a partial response to gefitinib
or erlotinib and subsequently developed resistance.36 The
amplification the MET gene caused activation of the HER3-
dependent intracellular pathways leading to the resistance.
These changes and potentially other molecular changes re-
lated to the treatment may have altered the clinical course or
the effectiveness of subsequent therapies of NSCLC in pa-
tients on this trial.
Preclinical models have investigated EGFR-TKI and
the anti-EGRR monoclonal antibody C225 therapy in com-
bination with radiation.37,38 Treatment with the C225 alone
and in combination with radiation therapy resulted in a
significant prolongation of tumor growth delay and local
control in comparison to control tumors. Treatment with
EGFR-TKI resulted in reduction of tumor volume, but did not
improve local control in comparison to control tumors. This
preclinical data suggests that anti-EGFR antibody direct ther-
apy may be more effective in combination with radiation
therapy than EGFR-TKI therapy in combination with radia-
tion therapy. The Radiation Therapy Oncology Group re-
cently performed a phase II trial of cetuximab (C225) in
combination with weekly carboplatin (AUC  2) and pacli-
taxel (45 mg/m2), followed by two cycles of carboplatin
(AUC  6) and paclitaxel (200 mg/m2) every 3 weeks.39
Ninety-three patients have been enrolled and 87 are evalu-
able, and median follow-up of 17.6 months. The 18-month
overall survival is 54.7%, and the primary toxicities were
grade 4 hematologic toxicities and grade 3 esophagitis. Fur-
ther follow-up and additional trials will be required to deter-
TABLE 5. Combined Modality Trials with Gefitinib
Trial N Chemotherapy or Induction Therapy TRT Dose Concurrent or Maintenance Therapy Median Survival
SWOG 002328 571 Cisplatin/etoposide with concurrent TRT 61 Maintenance
followed by docetaxel for 3 cycles Gefitinib (n  118) 23 moa
Placebo (n  125) 35 mo
Concurrent therapy
CALGB27 59b Carboplatin/paclitaxel gefitinib 66 Stratum 1 gefitinib 19 mo
Stratum 2 gefitinib daily, weekly carboplatin/
paclitaxel
12 mo
Australian29 28 None 60 Concurrent therapy NRd
Gefitinib daily, weekly carboplatin/paclitaxelc
a Median Survival time from randomization to gefitinib placebo (ie, after completion of concurrent chemoradiotherapy and 3 cycles of consolidation docetaxel).
b Stratum 1 (n  20), stratum 2 (n  39). Stratum 1 defined as PS 0–1 with  5% weight loss or PS  2; stratum 2 PS 0–1 with 5% weight loss.
c Chemotherapy dose escalation trials with all cohorts receiving gefitinib 250 mg daily; cohort 1 carboplatin (AUC  2) weekly alone, cohorts 2, 3, and 4 carboplatin (AUC 
2) weekly and paclitaxel 25, 35, 45 mg/m2 weekly, respectively. Cohort 4 expanded to 16 patients.
d Median survival has not been reached, survival at 24 mo follow-up was 60% (95% confidence intervals: 39–82%).
SWOG, Southwest Oncology Group; CALGB, Cancer and Leukemia Group B; TRT, Thoracic Radiation Therapy; NR, not reached.
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mine the toxicity and efficacy of EGFR directed antibodies in
stage III disease.
Our current trial did use the treatment paradigm of
induction chemotherapy, and the recent CALGB trial 39801
revealed a similar survival between concurrent chemoradio-
therapy and induction chemotherapy followed by concurrent
chemoradiotherapy (Table 4).24 The survival on both treat-
ment arms was lower than the survival seen on the previous
CALGB trial and other trials that employed induction che-
motherapy. It is possible that as concurrent chemoradiother-
apy within the United States has been become more widely
accepted the patient population enrolled on stage III clinical
trials has expanded to include patients who physicians pre-
viously would not have considered for this treatment paradigm,
and this contributed to the lower survival than previous trials.
The inclusion of patients with significant weight loss may have
adversely impacted the overall survival results of this trial; 17%
of patients enrolled on this trial had 5 to 10% weight loss, and
9% had 10% weight loss. Patients who had weight loss 5%
and who were otherwise eligible (n  87) on the concurrent
chemoradiotherapy and induction chemotherapy and concurrent
chemoradiotherapy arms had a median survival of 8 and 10
months, respectively, and 3-year survival rate of 10% and 23%,
respectively. The prevalence of patients with significant weight
loss may significantly influence the outcome of small phase II
trials of combined modality therapy.
Recent meta-analyses in the advanced NSCLC revealed
that cisplastin-based treatments have a superior overall sur-
vival, but a higher rate of toxicity when compared to carbo-
platin-based treatments.40,41 In stage III disease, the use of
cisplatin-based therapy may provide more effective treatment
for occult micrometastatic disease. The Hoosier Oncology
Group recently performed a phase III trial in which patients
received cisplatin and etoposide and thoracic radiation ther-
apy to 59.4 Gy, followed by randomization to consolidation
docetaxel versus observation.42 The median survival for all
patients was 21 months, and there was no significant differ-
ence in the median survival between the observation and
consolidation chemotherapy arm (24.2 versus 21.6 months,
respectively; p  0.94). The numerically longer survival on
the Hoosier Oncology Group than on CALGB 39801, the
potential advantages of concurrent systemic therapy with
thoracic radiation, and the data from meta-analyses from
advanced stage disease raises the possibility that cisplatin-
based treatment paradigms may be superior in stage III
disease. A phase III trial specifically designed to compare
cisplatin-based and carboplatin-based therapy would be re-
quired to definitively investigate this clinical question.
CONCLUSION
Induction chemotherapy with carboplatin, irinotecan,
and paclitaxel followed by concurrent carboplatin, paclitaxel,
and gefitinib and 3-dimensional TCRT to 74 Gy is feasible
with an acceptable toxicity profile. However, the survival on
this trial was disappointing in comparison to the survival seen
on our previous trials.
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